Clinical Trial Update: Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating devimistat in combination with mFFX for second-line metastatic pancreatic cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Devimistat (devimistat)
• mFFX (modified FOLFIRINOX) (modified FOLFIRINOX)

Snippet

Sponsor: Cornerstone Pharmaceuticals | Conditions: Pancreatic Cancer Stage IV | Phase 2 | Status: WITHDRAWN